In both cellular and mouse model, we identified that the MEK1/2 inhibitor Trametinib exhibited a significant anti-infection effect against Salmonella. Together, our findings underpin a key host-bacterial interplay mechanism and potential therapeutics for salmonellosis. The gene discussed is MAP2K1; the disease is salmonellosis.